A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
Sponsor: Precision BioSciences, Inc.
Terminated
Study was terminated due to lack of sufficient therapeutic effect
Other Relapsed/Refractory Multiple Myeloma trials with similar outcome
A PHASE1 clinical study on Relapsed/Refractory Multiple Myeloma, this trial is terminated or withdrawn. The trial is conducted by Precision BioSciences, Inc. and has accumulated 11 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE1
Status: Completed → Terminated · Phase: PHASE1_PHASE2 → PHASE1
-
Feb 2023 — Oct 2023 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
-
Sep 2021 — Feb 2023 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 6 earlier versions
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2021 — May 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
May 2020 — Aug 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2019 — May 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Precision BioSciences, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .